These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34922987)

  • 21. Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study.
    Cavarra M; Mason NL; Kuypers KPC; Bonnelle V; Smith WJ; Feilding A; Kryskow P; Ramaekers JG
    Eur J Pain; 2024 Jan; 28(1):153-165. PubMed ID: 37599279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Psychedelics in the field of chronic pain. A path to explore?].
    Molinard-Chenu A; Tsimploulis G; Penzenstadler L; Thorens G; Chytas V
    Rev Med Suisse; 2024 Feb; 20(861):342-344. PubMed ID: 38353434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach.
    Magaraggia I; Kuiperes Z; Schreiber R
    Neurobiol Learn Mem; 2021 Sep; 183():107467. PubMed ID: 34048913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychedelics as Medicines: An Emerging New Paradigm.
    Nichols DE; Johnson MW; Nichols CD
    Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do the therapeutic effects of psilocybin involve actions in the gut?
    Reed F; Foldi CJ
    Trends Pharmacol Sci; 2024 Feb; 45(2):107-117. PubMed ID: 38216431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The zebrafish for preclinical psilocybin research.
    Syed OA; Tsang B; Gerlai R
    Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
    Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D
    Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psilocybin for Trauma-Related Disorders.
    Khan AJ; Bradley E; O'Donovan A; Woolley J
    Curr Top Behav Neurosci; 2022; 56():319-332. PubMed ID: 35711024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
    Meccia J; Lopez J; Bagot RC
    Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Out of the box: A psychedelic model to study the creative mind.
    Kuypers KPC
    Med Hypotheses; 2018 Jun; 115():13-16. PubMed ID: 29685188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways.
    Sinha JK; Trisal A; Ghosh S; Gupta S; Singh KK; Han SS; Mahapatra M; Abomughaid MM; Abomughayedh AM; Almutary AG; Iqbal D; Bhaskar R; Mishra PC; Jha SK; Jha NK; Singh AK
    Ageing Res Rev; 2024 Apr; 96():102211. PubMed ID: 38307424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.